Acute Intracranial Hemorrhage clinical trials at UC Irvine

1 research study open to eligible people

Trial of Andexanet Alfa in ICH Patients Receiving an Oral FXa Inhibitor
open to eligible people ages 18 years and up
Randomized, controlled clinical trial evaluating the efficacy and safety of andexanet alfa versus usual care in patients with intracranial hemorrhage anticoagulated with a direct oral or indirect subcutaneous/intravenous anticoagulant
Orange, California and other locations

Last updated: April 11, 2022